Actualités, ressources, mises à jour
Une plateforme scientifique pour vous tenir informés de nos dernières recherches et de l'actualité de notre entreprise.
Une journée dans la vie de Tim Rodenburg, chef de produit chez InnoSer
Afin de proposer une gamme d’outils innovants destinés à accélérer le développement de médicaments, InnoSer rassemble des professionnels issus tant du monde scientifique que du monde des affaires. À travers notre série d’entretiens « Une journée dans la vie de », découvrons ensemble ce que signifie faire partie de cette petite…
InnoSer souhaite la bienvenue à Pascal Simoëns, son nouveau responsable du développement commercial
As of June 2020, Pascal Simoëns has joined InnoSer in the role of business development manager (BDM). Pascal will be translating InnoSer's products and services towards the fields of potential and existing client portfolios. By doing so, he will be creating a bridge...
InnoSer rejoint le projet « LEMONAID », financé par Eurostars
LEMONAID takes on the challenge of developing a new drug against Diffuse Large B-Cell Lymphoma (DLBCL) tumors to ultimately reduce drug resistance and relapse potential for patients. InnoSer supports this ambition by its expertise in combined in-vitro and in-vivo...
InnoSer vous donne rendez-vous à l'événement « Knowledge for Growth »
[EDIT]: This event is now hold digitally, and we are looking forward to talking to you at one of our virtual meetings. Detailed schedules to be announced soon! Organized by flanders.bio since it's establishment in 2004, knowledge for growth brings over 1300 biotech,...
InnoSer accueille Wim Tiest au poste de directeur technique
As of April 2020, Wim Tiest has joined InnoSer in the role of Chief Technology Officer (CTO) and as part of the company management team. Wim holds a MSc in biochemical engineering and in artificial intelligence, both from the KU Leuven. He has built his professional...
Évolutions de la plateforme oncologique PDX/O chez InnoSer
Despite the challenging times for the life sciences sector during coronavirus restrictions, we’ve been fortunate enough and well prepared to continue with the development of our PDX/O platform for oncology research. On a weekly basis we receive patient tumor samples...
info@innoserlaboratories.com
Liens rapides